Cigna Coverage Policy Lookup: How to Find the Right CP Number for Any Drug

What Is a Cigna Coverage Policy (CP) and Why It Matters

A Cigna Coverage Policy (CP) is a publicly available, numbered document that defines the medical necessity criteria Cigna uses to evaluate prior authorization and appeal requests for a specific drug, service, or procedure. Each CP lists the covered indications, required prior therapies, lab parameters, dosing limits, and exclusions Cigna will apply during review.

CPs matter because Cigna reviewers do not improvise. They open the relevant CP, walk through each criterion, and decide based on whether your documentation matches. An appeal that does not cite the CP number, and does not address each criterion in order, is reviewed superficially and usually upheld. An appeal that walks the reviewer through the CP criteria one by one with chart evidence wins more than half the time.

How to Access the cignaforhcp.cigna.com Coverage Policy Library

Coverage Policies are publicly accessible — a provider portal account is helpful but not required for CP lookup.

• ✓ Public access — go to cigna.com/health-care-providers/coverage-and-claims/policies
• ✓ Provider portal — log in at cignaforhcp.cigna.com and navigate to "Resources" → "Coverage Policies"
• ✓ Search by drug brand name, generic name, or CPT/HCPCS code
• ✓ Filter by "Medical" vs "Pharmacy" vs "Behavioral" policy library
• ✓ Each CP downloads as a PDF; the CP number appears in the document header (e.g., "Coverage Policy Number: CP-IP-0123")

Cigna Pharmacy vs Medical Coverage Policies — Different Sections

Cigna maintains separate Coverage Policy libraries for drugs administered under the pharmacy benefit (self-administered, dispensed by retail or specialty pharmacy) versus drugs billed under the medical benefit (clinician-administered, J-code billing).

The same molecule can have two different CPs. For example, a self-administered subcutaneous biologic shipped by Accredo follows a pharmacy CP managed by Express Scripts, while the same biologic billed via J-code in an infusion suite follows a medical CP managed by Cigna directly. Citing the wrong CP type is a common reason appeals are denied — the reviewer can't apply criteria from a CP that doesn't govern the requested benefit.

Common Drug Categories and Their CP Numbers

CP numbers are updated periodically, so always re-verify in the live library. Recent (2025-2026) examples illustrate the structure:

• ✓ Biologics for inflammatory disease (adalimumab, infliximab, etanercept) — typically pharmacy CPs in the CP-IP-01XX range; medical-benefit infliximab uses a separate medical CP
• ✓ GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) — separate pharmacy CPs by indication (T2DM vs chronic weight management vs OSA)
• ✓ Oncology agents — medical CPs aligned to NCCN compendia, often referencing NCCN Category 1 or 2A by recommendation number
• ✓ Specialty injectables (denosumab, ustekinumab, dupilumab) — usually pharmacy CPs with stepped therapy criteria
• ✓ Always document the CP number AND its publication/revision date on your appeal — Cigna reviewers will reject citations to outdated CP versions.

How to Cite the CP in Your Letter of Medical Necessity

The strongest LMN structure mirrors the CP itself. Open with one sentence stating patient, diagnosis, drug, and the exact CP number being addressed. Then create a sub-section for each numbered criterion in the CP and respond directly with chart evidence.

For example, if CP-IP-0123 requires (1) confirmed diagnosis with ICD-10, (2) failure of two prior therapies, (3) baseline disease severity score, and (4) prescriber specialty, your letter should have four labeled sub-sections that quote the criterion and provide the matching documentation. Reviewers can check off each criterion as they read — making approval the path of least resistance.

Cigna's Most-Cited Coverage Policies for Specialty Drugs

Across denials we analyze, a small number of CPs appear repeatedly because they govern the highest-volume specialty categories:

• ✓ CPs covering TNF inhibitors (rheumatology, dermatology, gastroenterology) — used for adalimumab, infliximab, etanercept, certolizumab, golimumab
• ✓ CPs covering IL-17/IL-23 inhibitors — used for secukinumab, ixekizumab, ustekinumab, risankizumab, guselkumab
• ✓ CPs covering JAK inhibitors — used for tofacitinib, baricitinib, upadacitinib (with pregnancy/cardiovascular warnings)
• ✓ CPs covering GLP-1 obesity drugs — semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda)
• ✓ CPs covering oncology biologics and targeted therapy — usually deferred to NCCN Category 1/2A
• ✓ Mastering the criteria for these high-volume CPs covers the majority of specialty appeal volume.

When Cigna Updates CPs and How to Track Changes

Cigna revises Coverage Policies on a quarterly cadence, with periodic interim updates when FDA approves new indications or new drugs become available. Each PDF lists "Effective Date" and "Last Reviewed Date" in the header — always check these before citing.

To track CP changes: subscribe to the Cigna provider newsletter, monitor the "Recently Updated" feed at cignaforhcp.cigna.com, and re-pull any CP cited in a pending appeal if the appeal will be filed more than 30 days after policy lookup. A CP that changed mid-appeal can derail an otherwise solid case if the criteria shifted.

Common update patterns: addition of newly FDA-approved drugs to step therapy alternatives, tightening of BMI or comorbidity thresholds for GLP-1s, alignment with new NCCN compendia versions for oncology, and removal of redundant prior-therapy steps when a guideline updates.

How RxCheckUp Maintains Live CP Mapping

RxCheckUp continuously re-indexes Cigna's Coverage Policy library so every prior auth and appeal generated through the platform cites the current CP number, the effective date, and the criteria as worded in the live PDF. When a CP changes, in-flight appeals are flagged and the new criteria are mapped automatically — eliminating the manual lookup step entirely.